Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies; administrative services for clinical trials; clinical trials for foods for specified health uses; and hospital support. It also conducts non-clinical studies for pharmaceuticals, medical devices, chemical substances, and food development using small and large animals. In addition, the company offers services related to mergers and acquisitions, business revitalization, business succession, and investment business. The company was formerly known as Trans Genic Inc. and changed its name to Transgenic Group Inc. in October 2024. Transgenic Group Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
Research context
Trans Genic Inc appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Trans Genic Inc is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Trans Genic Inc's total revenue rose by 17.7% to $3B since the same quarter in the previous year.
Its net income has increased by 2160.5% to $423M since the same quarter in the previous year.
Based on the above factors, Trans Genic Inc gets an overall score of 3/5.